Overview
Wpd Pharmaceuticals is focused on developing biological and chemical molecules for targeted therapy in brain glioma and other central nervous system cancers. The company has a former subsidiary in Poland that specializes in biotechnology research and development, particularly in oncology and medicinal products involving biological compounds and small molecules.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Bank accounts
Registered as a VAT taxpayer on 2017-11-29. Active
56 1050 1298 1000 0024 4174 7926- 37 1050 1298 1000 0090 8060 2189
- 79 1050 1298 1000 0090 3137 3351
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 21, 2022 | Call to creditors | |
| Feb 21, 2022 | Call to creditors |
Public aid
17 public aid cases recorded, with a total value of $22,342,028.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 5, 2025 | Aid for research and development projects: industrial research | $536.5K$536,451 | Prezes Agencji Badań Medycznych | |
| Apr 29, 2025 | Aid for research and development projects: industrial research | $550.6K$550,574 | Prezes Agencji Badań Medycznych | |
| Apr 29, 2025 | Aid for research and development projects: experimental development | $191.7K$191,688 | Prezes Agencji Badań Medycznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2021-01-01 | Nowatorskie podejście do terapii ostrej białaczki szpikowej (AML) | $5.3M$5,276,734 | Program Operacyjny Inteligentny Rozwój | |
| 2019-01-01 | Nowe podejście do terapii glejaka zaspokajające krytyczne potrzeby medyczne | $5.6M$5,604,432 | Program Operacyjny Inteligentny Rozwój | |
| 2018-01-01 | Rozwój nowego leku stosowanego w terapii glejaka wielopostaciowego | $5.9M$5,922,532 | Program Operacyjny Inteligentny Rozwój |
Tenders
1 tender recorded as contractor, with a total value of $48,496.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Mar 18, 2025 | ,,Wytworzenie białka rekombinowanego WPD101a wraz analizą oddziaływania białka WPD101a z receptorem IL-13Ra2” | $48,496$48,496 | Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan we Wrocławiu |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, declarations on behalf of the company are made by the member of the management board. In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 130,098 | $1,757,131.28 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Green ZebrasS.A. | $328,658.91 | whygreenzebras.pl | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Specjalistyczne Gabinetysp. z o.o. | $239,872.14 | specjalistycznegabinety.pl | ||
| Oncotarget Wojciech JurczakS.K.A. | $192,291.27 | oncotarget.pl | ||
| Gcp-Service International Ltd. & Co. KgBranch (foreign co.) | $159,376.34 | gcp-service.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Luna Laboratorysp. z o.o. | $61,894.23 | lunalab.pl | ||
| Receptonsp. z o.o. | $50,611.05 | receptonbiotech.com | ||
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com |
Change history
| Date | Event | |
|---|---|---|
| 2024-02-19 | Share capital change (5,784,900.00 PLN → 6,504,900.00 PLN) | |
| 2023-12-11 | Share capital change (5,108,700.00 PLN → 5,784,900.00 PLN) | |
| 2023-10-14 | Share capital change (2,100,000.00 PLN → 5,108,700.00 PLN) | |
| 2022-11-25 | Share capital change (400,000.00 PLN → 2,100,000.00 PLN) | |
| 2022-06-13 | Share capital change (2,969,200.00 PLN → 400,000.00 PLN) |
FAQ
Last updated: 2026-10-07